170485 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants; Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 B7 molecules, e.g. CD80, CD86
GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC)
#2PERSONALIZED CANCER VACCINES
#3SCORING METHODS FOR ANTI-PD THERAPY ELIGIBILITY AND COMPOSITIONS FOR PERFORMING SAME
#4USE OF EXTRACELLULAR VESICLES AND MICRONUCLEI OF CIRCULATING STROMAL CELLS AS PAN-CANCER BIOMARKERS FOR PREDICTING CLINICAL OUTCOMES
#5METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
#6THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#7BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#8COMPOSITIONS AND METHODS FOR DETECTION OF METASTASIS
#9NEUTRALIZATION ANTIBODY ASSAY METHOD
#10B7H3 BINDERS
#11ANTI-CD40 ANTIBODY, ANTI-PD-L1×CD40 BISPECIFIC ANTIBODY, AND USE THEREOF
#12ANTI-VISTA ANTIBODIES AND FRAGMENTS
#13IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#14METHOD FOR IDENTIFYING CANCER PATIENTS THAT BENEFIT FROM ANTI-CLEVER-1 TREATMENT
#15ANTI-GDF15 ANTIBODY USED IN A COMBINATION TREATMENT OF SPECIFIC PATIENT GROUPS AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
#16COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#17Combination Of Proteotypic Peptides For The Detection Of Proteins In The Pd-L1 Axis
#18THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#19TREATMENT OF SOLID TUMORS
#20METHOD FOR PREDICTING PATIENT RESPONSE TO IMMUNOTHERAPY
#21PREDICTIVE RESPONSE BIOMARKER DISCOVERY PROCESS
#22USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES
#23NOVEL BIOMARKER VISTA FOR DIAGNOSIS AND PROGNOSIS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
#24BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#25ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#26METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1
#27BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#28METHODS AND SYSTEMS FOR PREDICTING RESPONSE TO PD-1 AXIS DIRECTED THERAPEUTICS IN COLORECTAL TUMORS WITH DEFICIENT MISMATCH REPAIR
#29USE OF BMMF1 REP PROTEIN AS DIAGNOSTIC MARKER FOR LUNG CANCER
#30BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#31ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF IN CELL THERAPY
#32BIOMARKERS FOR PREDICTING ELIGIBILITY FOR AN ANTI-ILT4 AND ANTI-PD-1 COMBINATION THERAPY
#33METHOD OF PREDICTING A PATIENT'S BENEFIT FROM THERAPY WITH AN IMMUNE CHECKPOINT INHIBITOR
#34K17 AS A BIOMARKER FOR TUMOR RESPONSE TO IMMUNOTHERAPY
#35METHODS FOR PREDICTING AND/OR MONITORING CANCER TREATMENT RESPONSE USING CHANGES IN CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS)
#36ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES
#37THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#38BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#39FULLY HUMAN ANTIBODY FOR HUMAN B7H3, CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#40B7H6 ANTIBODY AND USE THEREOF
#41THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#42ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF
#43METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER
#44Methods of assaying neoplastic and neoplasia-related cells and uses thereof
#45PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER
#46METHODS AND COMPOSITIONS FOR IN SITU IMMUNE PROFILING OF HEART TRANSPLANT BIOPSIES
#47Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors
#48METHODS OF DIAGNOSING AND TREATING LUPUS
#49Binding Members to PD-L1
#50TARGETING DNA-PKCS AND B7-H1 TO TREAT CANCER
#51ANTI-PD-L1 AND PD-L2 ANTIBODY AND DERIVATIVES AND USE THEREOF
#52IMMUNE STATUS BIOMARKERS AND USES THEREFOR
#53SCORING METHODS FOR ANTI-PD THERAPY ELIGIBILITY AND COMPOSITIONS FOR PERFORMING SAME
#54USES OF BIOMARKERS FOR IMPROVING IMMUNOTHERAPY
#55BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#56METHOD FOR DETECTING TUMOR CELL SURFACE MARKER MOLECULE PD-L1
#57PREDICTIVE LIQUID MARKERS FOR CANCER IMMUNOTHERAPY
#58IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#59TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY
#60ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF
#61METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
#62COMPOSITIONS AND METHODS FOR TREATING CEREBRAL VASOSPASM
#63PDL1 POSITIVE NK CELL CANCER TREATMENT
#64IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#65Antibodies specific to glycosylated PD-L1 and methods of use thereof
#66Anti-PD-L1 antibodies and variants
#67NOVEL ANTI-PD-L1 ANTIBODY AND USES THEREOF
#68CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEINS FOR TREATING PD-L1 NEGATIVE TUMORS
#69PD-L1 binding polypeptides for imaging
#70Anti-B7-H3 monoclonal antibody and use thereof in cell therapy
#71METHOD FOR PROVIDING INFORMATION ON THERAPEUTIC REACTION OF CANCER IMMUNOTHERAPY AND KIT USING SAME
#72Anti-VISTA antibodies and fragments
#73Biomarker composition for predicting cancer malignant prognosis induced by microplastic exposure
#74DATA PROCESSING SYSTEM FOR IDENTIFYING A THERAPEUTIC AGENT
#75Anti-B7-H1 antibodies for treating tumors
#76Anti-PD-L1 antibodies and use thereof
#77B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
#78Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
#79B7-H4 antibodies and methods and use thereof
#80Methods of assaying neoplastic and neoplasia-related cells and uses thereof
#81Agents and methods for predicting response to therapy
#82Information Acquisition Method For Diagnosis or Treatment Of Cancer or Immune System-Related Diseasees
#83Soluble B7-H1
#84Peptides for molecular detection of PD-L1
#85MOLECULAR PROFILING FOR CANCER
#86Methods and materials for assessing and treating cancer
#87Scoring methods for anti-PD therapy eligibility and compositions for performing same
#88IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#89Anti-CD276 antibodies (B7H3)
#90Methods of treatment with CD80 extracellular domain polypeptides
#91DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
#92Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
#93Targeting DNA-PKCS and B7-H1 to treat cancer
#94METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY
#95Anti-B7-H3 antibodies and diagnostic uses thereof
#96Therapeutic and diagnostic methods for cancer
#97B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
#98Isolated B7-H4 specific compositions and methods of use thereof
#99MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS
#100Synthetic library of specific binding molecules
#101FLOW PROTEOMETRIC METHODS FOR DIGITAL QUANTIFICATION AND BINDING ANALYSIS
#102DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES
#103PD-L1 binding polypeptides for imaging
#104PBRM1 biomarkers predictive of anti-immune checkpoint response
#105Anti-B7-H1 antibodies for treating tumors
#106METHODS AND KITS FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO IMMUNOTHERAPY
#107Molecular Profiling of Immune Modulators
#108Anti-PD-L1 antibodies and variants
#109Diagnostic anti-PD-L1 antibody and use thereof
#110Methods of using PD-L1 expression in treatment decisions for cancer therapy
#111Method for identifying a bacterial infection
#112METHODS OF DIAGNOSING AND TREATING LUPUS
#113Binding members to PD-L1
#114Therapeutic and diagnostic methods for cancer
#115Collapsible element pocket former
#116Collapsible element pocket former
#117Methods of identifying immune cells in PD-L1 positive tumor tissue
#118INTERCELLULAR LABELING OF LIGAND-RECEPTOR INTERACTIONS
#119BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#120Anti-VISTA antibodies and fragments
#121Genome-scale T cell activity array and methods of use thereof
#122METHOD FOR DETERMINING CANCER
#123Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
#124IDENTIFICATION OF PATIENTS IN NEED OF PD-L-1 INHIBITOR COTHERAPY
#125COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#126Immune checkpoint molecular fitness profiling by mass spectrometry
#127PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
#128Anti-CD276 antibodies (B7H3)
#129Antibody molecules to PD-L1 and methods of treating cancer
#130Methods of detecting per cell PD-L1 expression and uses thereof
#131Antibodies specific to glycosylated PD-L1 and methods of use thereof
#132Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
#133Methods of determining patient populations amenable to immunomodulatory treatment of cancer
#134MOLECULAR PROFILING FOR CANCER
#135Compositions and methods for expressing polypeptides on the surface of cells
#136THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#137METHOD FOR SIMULTANEOUSLY ANALYZING BLOOD CELLS HAVING INTERACTIVE MOLECULES
#138METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
#139METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
#140MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
#141Soluble B7-H1
#142Histochemical assay for evaluating expression of programmed death ligand 1 (PD-L1)
#143Scoring methods for anti-PD therapy eligibility and compositions for performing same
#144Method of treating CD155 expressing cancers
#145PD-L1 binding polypeptides for imaging
#146METHOD FOR PRODUCING AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS (TOLDCS) WITH SPECIFIC ANTIGENS AND THEIR USE IN THE PREPARATION OF A MEDICAMENT USEFUL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
#147MOLECULAR PROFILING OF IMMUNE MODULATORS
#148Targeting DNA-PKcs and B7-H1 to treat cancer
#149B7-H3 IN CANCER
#150Distinguishing antagonistic and agonistic anti B7-H1 antibodies
#151Anti-B7-H3 antibodies and diagnostic uses thereof
#152BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#153Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and method of prognosticating survival rate in glioblastoma mulztiforme patient after treatment
#154Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
#155Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
#156METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
#157Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
#158VISTA antagonist and methods of use
#159Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
#160CD86 variants with improved affinity for CTLA-4
#161Anti-B7-H1 antibodies for treating tumors
#162Isolated B7-H4 specific compositions and methods of use thereof
#163Biomarkers and methods of treating PD-1 and PD-L1 related conditions
#164Screening method for inhibitors of binding of zBR7R1 to CD155
#165Synthetic library of specific binding molecules
#166SYSTEMS AND METHODS FOR ASSESSING MODULATORS OF IMMUNE CHECKPOINTS
#167Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
#168RECEPTORS FOR B7-H4
#169COMPOSITIONS AND METHODS FOR TREATING CANCER
#170Antibody molecules to PD-L1 and uses thereof
#171Immunomodulators
#172Intercellular labeling of ligand-receptor interactions
#173Immunoassay for soluble PD-L1
#174Isolation of therapeutic target specific VNAR domains to ICOSL
#175B7-H4 EXPRESSION ON TUMOR VASCULATURE
#176Method for identifying a bacterial infection
#177Antibodies that bind to human programmed death ligand 1 (PD-L1)
#178B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER
#179Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level
#180CANCER PROGNOSTIC ASSAYS
#181Soluble B7-H1
#182B7-H6 therapeutically active monoclonal antibody against B7-H6 polypeptide
#183Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
#184Anti-CD80 antibody
#185COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#186Anti-CD86 antibody
#187B7-H1 antibodies and method of use
#188B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER
#189PD-1, A Receptor for B7-4, and Uses Therefor
#190COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#191B7-H3 IN CANCER
#192B7-H1 Antibodies
#193B7-H1, a novel immunoregulatory molecule
#194Soluble B7-H1
#195COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#196Methods for screening for compounds that modulate PD-1 signaling
#197Assay for Antibodies
#198B7-H4 expression on tumor vasculature
#199CD86 and CD80 receptor competition assays
#200Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof
#201Compositions and methods for modulating immune responses
#202Assay for Antibodies
#203Assay for antibodies
#204Systems and methods for measuring changes in cellular activity in live tissue
#205Anti-B7-H3 antibody and use thereof